SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Lone Star Bio
Money on the Move: November 10 – 16
Investors are falling in with these biotech companies, dropping dollars to fuel their work for the latest advancement in life sciences.
November 17, 2021
 · 
3 min read
 · 
Kate Goodwin
Stefan Postles/Getty Images
Policy
Seniors Bear Burden of Biogen’s Alzheimer’s Drug in Medicare Price Hike
Thanks partly to Biogen’s pricey new Alzheimer’s drug, Medicare enrollees will be burdened with higher monthly premiums for their Part B coverage.
November 15, 2021
 · 
3 min read
 · 
Kate Goodwin
VDB Photos/Shutterstock
BioForest
Gates Foundation Pours $90 Million into Promising New Pneumococcal Vaccine
The Bill & Melinda Gates Foundation is taking up the cause for pneumococcal infection with a $90 million investment in Seattle area’s Inventprise.
November 11, 2021
 · 
3 min read
 · 
Kate Goodwin
Business
Money on the Move: November 3 – 9
Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here’s who snagged funding this week.
November 10, 2021
 · 
4 min read
 · 
Kate Goodwin
Deals
Arbor Scores $215 Million for Next-Gen CRISPR Toolbox
Arbor announced an oversubscribed Series B raise totaling $215 million, a significant increase from their initial $15.6 milllion Series A round to test for liver and CNS diseases.
November 9, 2021
 · 
2 min read
 · 
Kate Goodwin
Why Flu Vaccines are Recommended Despite Low Efficacy
While some get the jab faithfully each flu season, about half of the American population declines, likely over doubts of the vaccine’s effectiveness and necessity.
November 8, 2021
 · 
4 min read
 · 
Kate Goodwin
Business
Bespoke Consortium Born to Bring Gene Therapy to Rare Diseases
Collaboration is key to faster breakthroughs. The NIH, FDA, and 15 private organizations have announced they are joining forces for the sake of the 30 million Americans suffering from a rare disease.
October 28, 2021
 · 
3 min read
 · 
Kate Goodwin
Business
Money on the Move: October 20 – 26
While the volatility of the market has some shying away from going public, private investment dollars are still rolling in each week. Check out our top picks.
October 27, 2021
 · 
4 min read
 · 
Kate Goodwin
Pharm Country
Investor Cash Windfall to Lengthen Lifespans, Print DNA and Fight Cancer
Cambrian Biopharma announced an oversubscribed $100 million Series C. The biotech aims to prevent age-related diseases and increase healthy lifespans.
October 26, 2021
 · 
4 min read
 · 
Kate Goodwin
Business
BMS Buyout Rumors Send Canadian Biopharma’s Stock Soaring
Bristol Myers Squibb is reportedly courting Canada’s Aurinia Pharmaceuticals to strike a buyout deal.
October 25, 2021
 · 
2 min read
 · 
Kate Goodwin
Gates MRI Signs On to Guide Atreca’s Malaria Antibody Home
Atreca announced it is licensing its preclinical monoclonal antibody for the prevention of malaria to the Gates Medical Research Institute (MRI) for development.
October 22, 2021
 · 
2 min read
 · 
Kate Goodwin
Drug Development
Vaccine Manufacturers Practicing for Worse COVID-19 Variants to Emerge
Winter is quickly approaching in the U.S. Vaccine makers aren’t taking a wait-and-see approach but actively preparing for what may come next.
October 21, 2021
 · 
3 min read
 · 
Kate Goodwin
Business
Money on the Move: October 13 – 19
Investors can take their pick of life sciences companies, with more innovative ideas and treatments being added to pipelines daily. Here’s who brought in the sheaves this week.
October 20, 2021
 · 
3 min read
 · 
Kate Goodwin
Andreas Arnold/picture alliance via Getty Images
Deals
Boehringer Ingelheim Steps Up to the Plate for Cystic Fibrosis Patients
Choosing to exercise its options with a group of research and development partners, the pharma giant will accelerate a promising new C.F. gene therapy.
October 19, 2021
 · 
2 min read
 · 
Kate Goodwin
The erosive esophagitis drug vonoprazan indicated
Drug Development
Phathom Ready to Run Third NDA for Acid-Blocking Drug Vonoprazan
Phathom announced positive results from its Phase III trial, PHALCON-EE, comparing vonoprazan against lansoprazole in patients with moderate to severe erosive esophagitis.
October 18, 2021
 · 
2 min read
 · 
Kate Goodwin
Load More